Sep 2026· European Journal of Preventive Cardiology· 0 citations
Medicine
TL;DR
Low-grade inflammation was associated with MACE and all-cause mortality, independently of classical risk factors, in individuals recently diagnosed with type 2 diabetes and without prevalent CVD.
Abstract
Aims
This study aimed to investigate the prospective associations of interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), and high-sensitivity C-reactive protein (hsCRP) levels with major adverse cardiac event (MACE) and mortality in individuals recently diagnosed with type 2 diabetes and without prevalent CVD.
Methods
We included 7630 individuals recently diagnosed with type 2 diabetes (median duration 0.9 years) with a median age of 60 years (44% females). Individuals with prevalent CVD (n=1390) were excluded from the primary analyses modelling Fine-Gray subdistribution hazard regressions accounting for competing risk of non-CVD death and adjusting for classical risk factors (e.g. diabetes duration, smoking, alcohol, physical activity, waist circumference, LDL cholesterol, HbA1c, systolic blood pressure, eGFR, and pharmacological treatment). Subsequently, we evaluated the predictive ability of adding low-grade inflammation to a model containing classical risk factors.
Results
Median follow-up time was 9 years. A 1-SD increase in log-IL-6 (1.98 pg/mL), log-TNF-α (1.40 pg/mL) and log-hsCRP (3.28 mg/L) was associated with HRs of 1.16 (95% CI 1.09, 1.23), 1.01 (0.95, 1.08), and 1.16 (1.09, 1.25) for MACE and 1.38 (1.31, 1.45), 1.16 (1.10, 1.22), and 1.34 (1.25, 1.43) for all-cause mortality, respectively. Prediction of both MACE and all-cause mortality was slightly improved by adding IL-6 and hsCRP to the model alongside classical risk factor.
Conclusions
Low-grade inflammation was associated with MACE and all-cause mortality, independently of classical risk factors, in individuals recently diagnosed with type 2 diabetes and without prevalent CVD. Despite improved predictive ability of IL-6 and hsCRP, the absolute improvement was sparse.
In T2DM, LDL-C burden and variability jointly identified patients at greater risk, especially for MI and cardiovascular mortality, especially in younger adults or longer-duration diabetes subgroups.
Dae-Jeong Koo, J. Park, Kyungdo Han et al.· Diabetes, obesity and metabo...· 0 citations
Objectives: Individuals with type 2 diabetes (T2D) remain at high cardiovascular disease (CVD) risk. The pan-immune-inflammation value (PIV) integrates circulating neutrophils, monocytes, platelets, and lymphocytes but does not capture albumin-related nutritional and inflammatory reserve. We investigated associations b...
Fang-Kun Liu, Xing-Hua Yang, Bo Gao et al.· Biomedicines· 0 citations
A combined inflammatory–metabolic profile identified patients with T2DM who experienced subsequent cardiovascular events and may provide complementary information when used alongside standard cardiovascular risk assessment.
Ahmad Azhar, Yousaf Khan, Muhammad Huzaifa· DEVELOPMENTAL MEDICO-LIFE-SC...· 0 citations
In newly diagnosed type 2 diabetes without overt complications, higher fasting C-peptide and lower TcPO2 were associated with increased cardiovascular risk and these findings are hypothesis-generating and warrant external validation.
C. Gazzaruso, P. Gallotti, Colomba Falcone et al.· Acta Diabetologica· 0 citations
IL-6 and ApoB were independently associated with cardiovascular events, with atherogenic lipoprotein burden predominating for MI and inflammatory signaling for cardiovascular and all-cause death.
P. Cheon, J. McParland, Sean Doherty et al.· Progress in cardiovascular d...· 1 citation
AIMS
To determine how high-sensitivity C-reactive protein (hsCRP) and lipoprotein(a) [Lp(a)] predict major adverse cardiovascular events (MACE) across the spectrum of baseline cardiovascular risk.
METHODS
UK Biobank participants were grouped according to baseline cardiovascular risk. The primary endpoint was first MA...
B. Tucker, Leung-Ong Kwok, Thomas Payne et al.· Atherosclerosis· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.